Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents

Jacob D. Peuler and Laura E. Phelps

Department of Pharmacology, Midwestern University, Downers Grove, IL, USA

Submitted December 2, 2014; accepted in final form March 16, 2015

Abstract

Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. By preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, these inhibitors also enhance arterial vasorelaxant effects of nitric oxide donors (which stimulate cGMP synthesis). In the present work, we confirmed this enhancing effect after co-administration of sildenafil with nitroprusside to freshly-isolated rat tail arterial tissues. However, in the same tissues we also observed that sildenafil does not enhance but rather attenuates vasorelaxant effects of three commonly-used antidiabetic drugs, i.e. the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. Indeed, sildenafil completely blocked vasorelaxant effects of low concentrations of these drugs. In addition, we found that this same novel anti-vasorelaxant interaction of sildenafil with these agents was abolished by either 1) omitting extracellular glucose or 2) inhibiting specific smooth muscle glycolytic pathways; pathways known to preferentially utilize extracellular glucose to fuel certain adenosine triphosphate (ATP)-dependent ion transporters: e.g. ATP-sensitive K channels, sarcoplasmic reticulum Ca-ATPase, plasma membrane Ca-ATPase and Na/K-ATPase. Accordingly, we suspect that altered activity of one or more of these ion transporters mediates the observed attenuating (anti-vasorelaxant) interaction of sildenafil with the antidiabetic drugs. The present results are relevant because hypertension is so common and difficult to control in Type 2 diabetes. The present data suggest that sildenafil might interfere with the known antihypertensive potential of metformin and the thiazolidinediones. However, they do not suggest that it will interact with them to cause life-threatening episodes of severe hypotension, as can occur when it is co-administered with nitrates.

Key words: metformin, pioglitazone, rosiglitazone, glucose, glycolysis
Introduction

It is now widely recognized that sildenafil interacts with organic nitrates and other nitric oxide (NO)-donors to markedly enhance their inherent arterial vasodilatory (vasorelaxant) activity (1–10). This interaction can potentially cause life-threatening episodes of severe hypotension (11). While more than one mechanism may be involved, it is generally assumed that this type of interaction is due largely to the ability of sildenafil to inhibit degradation of NO-induced increases in cyclic guanosine monophosphate (cGMP) in arterial smooth muscle (1–10). In addition, this interaction can be demonstrated with relatively low yet therapeutically-effective concentrations of sildenafil that have little or no systemic arterial relaxant activity of their own (1, 5, 7, 10, 12) and it is particularly easy to demonstrate in vitro with intact arterial vascular preparations freshly isolated from animal models (2, 4, 5, 7, 8, 10). Accordingly, other studies have been conducted to determine if sildenafil interacts similarly with nonnitrate vasorelaxant agents which are commonly used to treat hypertensive patients (13). However, no attention has been given to whether sildenafil interacts with those particular types of antidiabetic agents that are known to possess direct vasorelaxant properties independent of their antihyperglycemic effects. Thus, the goals of the present study were to determine whether such interactions exist and, if so, to begin exploring mechanisms responsible for them.

The antidiabetic agents in question are the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. At high concentrations, well above levels observed in plasma of diabetic patients (14–16), their relaxation of isolated arterial vascular tissues in vitro occurs rapidly (17–21). At lower, more therapeutically-relevant concentrations, the appearance of their relaxant action in vitro can be delayed for a number of hours (19, 21–23). We tested for the ability of sildenafil to interact with the latter because it is more clinically relevant. Our results will obviously have important implications for the use of sildenafil in adult diabetic men; a large population in which erectile dysfunction is common (24) and begins early affecting more than half of all patients before the age of 60 (25).

Materials and Methods

Preparation of arterial tissues

Sildenafil’s ability to enhance nitrate-induced arterial relaxation has been demonstrated repeatedly in vitro with intact vascular rings prepared from animal aorta (1, 7, 8, 10). However, we will employ rings from the ventral tail artery of the laboratory rat since all of our previous experiments with direct vasorelaxant properties of metformin and the thiazolidinediones were successfully performed with that particular preparation (18–23). In addition, while certainly much smaller, the rat tail artery is also more muscular and richer in adrenergic nerve endings and receptors than the aorta and, as such, more closely resembles systemic arterial resistance vessels (26–28). Also, its notable length allows for the preparation of several rings with nearly identical contractile properties from a single vessel. Accordingly, ventral tail arteries were isolated from adult male Sprague-Dawley rats after euthanizing them by procedures approved in advance by the Institutional Animal Care and Use Committee of Midwestern University. On each experimental day, a short uniform portion of a single artery would then be cleaned and carefully sectioned into multiple 3-mm cylindrical rings using a bound set of evenly-spaced scalpel blades. In our experience, individual rings sectioned in this manner exhibit more uniform contractile responses than if sectioned with multiple cuts by a single blade. A maximum of eight rings were selected at random for experimental treatments on each particular day. [Eight was the largest number that our in vitro bath system and Grass recorder could accommodate on any given day]. Each ring was mounted
between two tungsten wire stirrups which in our experience were strong enough not to bend during ring contractions yet thin enough not to damage the inner endothelial cell layer (18–23). Then, each ring was suspended in a 40 ml tissue bath and equilibrated for several minutes before experimentation at a resting (baseline) tension of 1000 mg in standard physiological (Krebs) buffer which was warmed to 37°C and gassed to pH 7.4 with regulated delivery of O₂/CO₂.

Experiments with glucose present and glycolysis intact

Initial experiments were performed to find a concentration of sildenafil that would not cause vasorelaxation by itself but yet significantly enhance vasorelaxant effects of nitroprusside in norepinephrine-contracted vascular rings prepared from tail arteries of adult male rats (See Preparation of arterial tissues). We found that 200 nmol/l (95 ng/ml) was best suited for that purpose (data not shown). This is well within the range of sildenafil’s plasma concentrations typically found in patients after oral administration (29). Then we examined additional rat tail arterial rings in 3 more experiments for the ability of this same level of sildenafil to interact with the abovementioned vasorelaxant effects of 1) metformin, 2) pioglitazone and 3) rosiglitazone (Fig. 1–3). In each of these 3 separate experiments, some rings were incubated for 4 h in the presence of sildenafil’s vehicle with either one of these antidiabetic agents or its vehicle, while other rings were incubated similarly but in the presence of the 200 nmol/l sildenafil. All incubations (renewed hourly) were carried out with standard Krebs buffer (with glucose present). After 4 h, all rings were contracted with stepwise cumulative administration of norepinephrine as shown in Figs. 1–3. The various experimental agents remained present during this administration of norepinephrine (which required 15 min to complete).

Experiments with glucose absent and glycolysis inhibited

We then conducted two additional experiments to evaluate the role of extracellular glucose and its glycolytic metabolism in the findings gathered from the experiments described above. In both, we re-administered sildenafil along with metformin at 50 µmol/l, pioglitazone at 5 µmol/l and rosiglitazone at 10 µmol/l; concentrations which after 4 h in Figs. 1–3 had produced relaxations that sildenafil clearly abolished. In the first of
these additional experiments (Fig. 4), we omitted extracellular glucose starting 1.5 h before norepinephrine. We chose to wait 1.5 h to allow transient increases in baseline arterial tensions (which occurred only occasionally in response to the glucose omission) to fully dissipate before administering norepinephrine. Longer periods were avoided because even though arterial smooth muscle is known to retain as much as half its normal content of glycogen ("stored" glucose) after 3 h of glucose omission (30, 31), control norepinephrine contractions in our tissues were compromised too much (after 3 h) for our purposes. In the second additional experiment (Fig. 5), we did not omit extracellular glucose. Rather, at 1.5 h before norepinephrine, we administered the glycolysis inhibitor iodoacetate at a low level (30 µmol/l); thus, similar to the 50 µmol/l which in arterial smooth muscle is reported to specifically inhibit only the lactate-producing glycolytic pathways that
preferentially utilize extracellular glucose to fuel membrane-bound ATP-dependent ion transporters, not the cytoplasmic glycolysis that normally metabolizes intracellularly-stored glucose (glycogen) to acetyl-CoA for mitochondrial production of ATP for contractile proteins (32, 33). Complete inhibition of all arterial smooth muscle glycolysis requires 1000 µmol/l iodoacetate (32), which was not used because it abolishes all contractile function in the rat tail artery.

---

**Fig. 4.** Effects of 4-h co-administration of sildenafil with antidiabetic agents on norepinephrine (NE) contractions in vascular rings prepared from 12 rat tail arteries. Extracellular D-glucose was omitted from all incubation buffers starting 1.5 h before NE. All agents significantly reduced (relaxed) the force of NE contractions as determined by 2-factor ANOVA (*P<0.05 versus vehicles at all levels of NE from 10^{-7} to 10^{-4} mol/l). That same ANOVA did not reveal interactive effects of sildenafil on these relaxant effects of the antidiabetic agents.

**Fig. 5.** Effects of 4-h co-administration of sildenafil with antidiabetic agents on norepinephrine (NE) contractions in vascular rings prepared from 12 rat tail arteries. Iodoacetate (30 µmol/l) was administered to all incubation buffers starting 1.5 h before NE. All agents significantly reduced (relaxed) the force of NE contractions as determined by 2-factor ANOVA (*P<0.05 versus vehicles at all levels of NE from 10^{-7} to 10^{-4} mol/l). That same ANOVA did not reveal interactive effects of sildenafil on these relaxant effects of the antidiabetic agents.
Viagra and antidiabetic agents

Analysis of data

At each level of norepinephrine administered in the above experiments, the numerical values describing its contractile force (expressed in milligram units) were summarized as mean ± S.E.M. and then subjected (at each level of norepinephrine separately and from both sides A and B of each figure together) to 2-factor analysis-of-variance (ANOVA) to determine statistically significant effects of sildenafil (factor one) on the relaxant effects of each antidiabetic agent (factor two). Effects were considered statistically significant if the standard probability of error ($P$ value) was less than 0.05.

Results

Experiments with glucose present and glycolysis intact

There were no changes in baseline arterial tension caused by sildenafil or any of the antidiabetic agents (either separately or combined) during the 4-h co-administration periods preceding administration of norepinephrine to rat tail arterial rings in these experiments. During administration of norepinephrine ($10^{-10}$ to $10^{-4}$ mol/l) the following results were observed (data in all figures are illustrated as mean ± S.E.M.). As shown in Fig. 1 (A, left side), metformin significantly reduced (relaxed) the force of norepinephrine contractions at all levels of treatment, i.e. 25, 50 and 100 µmol/l metformin. But as also shown in Fig. 1 (B, right side), sildenafil abolished the relaxant effects of the 25 and 50 µmol/l metformin and partially but significantly attenuated the greater relaxant effect of 100 µmol/l metformin (by 36% overall from $10^{-8}$ to $10^{-4}$ mol/l norepinephrine).

Similarly, pioglitazone significantly relaxed norepinephrine contractions at all levels of treatment, i.e. 5, 10 and 20 µmol/l pioglitazone (Fig. 2A, left side). Sildenafil completely abolished the relaxant effect of the 5 µmol/l pioglitazone and partially attenuated that of the 10 and 20 µmol/l pioglitazone (by 38% and 30%, respectively, overall from $10^{-8}$ to $10^{-4}$ mol/l norepinephrine) (Fig. 2B, right side). Similar results were seen with rosiglitazone (Fig. 3 A and B). Sildenafil abolished a statistically significant relaxant effect of 10 µmol/l rosiglitazone (Fig. 3B). Thus, while exerting little if any vasorelaxant effect on its own, a therapeutically-relevant concentration of sildenafil appeared to interact nonspecifically with all three antidiabetic agents, interfering with the ability of each to relax norepinephrine contractions in isolated arterial tissues (the exact opposite of its interaction with nitrovasodilators).

Experiments with glucose absent and glycolysis inhibited

As expected, omission of extracellular glucose reduced control contractions of norepinephrine (see Fig. 4 versus Fig. 1–3), but it also unmasked notably greater relaxant effects of the antidiabetic drugs (particularly the two thiazolidinediones). In addition, with glucose omitted, sildenafil failed to abolish these relaxant effects (Fig. 4B). As seen in Fig. 5, 30 µmol/l iodoacetate did not suppress control norepinephrine contractions nearly as much as the glucose omission in Fig. 4. Yet, it had nearly the same impact on antidiabetic drug and sildenafil effects as seen with glucose omission. Most importantly, sildenafil failed to abolish the relaxant effects of the antidiabetic agents in the presence of the iodoacetate. Finally, in a limited number of additional tests (not shown), neither glucose omission nor iodoacetate influenced vasorelaxations produced by other commonly-used vasodilators, such as the calcium channel blocker nifedipine. Thus, their impact on sildenafil/antidiabetic drug effects may be unique and not a common phenomenon for all vasodilatory agents.
Discussion

**New findings**

Type 2 diabetic men commonly experience erectile dysfunction (24) for which phosphodiesterase type 5 (PDE5) inhibitors like sildenafil are often recommended (34–36). By preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, these PDE5 inhibitors also enhance arterial vasodilatory (vasorelaxant) effects of organic nitrates and other nitric oxide (NO) donors which stimulate cGMP synthesis (1–10). In our experiments, we observed this enhancing effect *in vitro* in norepinephrine-contracted vascular tissue rings (prepared from tail arteries of adult male rats) after exposing them for four hours to co-administration of 200 nmol/l sildenafil (a level typical of plasma concentrations in humans after oral administration, 29) and the NO-donor nitroprusside. However, in the same tissues we also observed that 4-h exposure to the same level of sildenafil does not enhance but rather attenuates vasorelaxant effects of three important oral antidiabetic drugs commonly used to improve glucose metabolism in type 2 diabetic patients, i.e. the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. Indeed, sildenafil completely blocked vasorelaxant effects of low concentrations of these drugs. In additional experiments, we found that this same novel anti-vasorelaxant interaction of sildenafil with these antidiabetic drugs was abolished by either 1) omitting extracellular glucose or 2) inhibiting specific vascular smooth muscle glycolytic pathways; pathways known to preferentially utilize extracellular glucose to fuel the following adenosine triphosphate (ATP)-dependent ion transporters: ATP-sensitive K channels, sarcoplasmic reticulum Ca-ATPase, plasma membrane Ca-ATPase and Na/K-ATPase (37–45).

**Potential mechanisms**

Among the various types of oral antidiabetic agents currently used in the treatment of hyperglycemia in type 2 diabetes, there are some that stimulate insulin secretion (e.g. sulfonylureas) and some that mimic and/or improve insulin action (the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone) (46–50). Only agents of the latter type are known to exert direct vasodilatory (vasorelaxant) effects on the arterial vessel wall (17–23, 49, 51–58); effects now recognized as largely responsible for their antihypertensive action (49, 54–58). Also, the full expression of their vasorelaxant effects (at least with low, therapeutically-relevant concentrations) is delayed for a number of hours (19, 21–23). In our laboratory at least 4 h is required for the full effect of each agent. But this does not readily explain why sildenafil would antagonize relaxant effects of these antidiabetic drugs as seen in our initial set of experiments.

Most evidence indicates that metformin and thiazolidinediones dilate arterial vessels by activating relaxant mechanisms within the smooth muscle cell itself; the most studied being voltage-operated ion channels. Both reduce arterial smooth muscle calcium (Ca) influx by inhibiting voltage-operated Ca channels (17, 51–53). Evidence shows that thiazolidinediones do so largely directly (21, 51–53) while metformin does so only indirectly, i.e. by repolarizing arterial smooth muscle cell membranes (17) due to activation of voltage-dependent K channels (20). However, we found it difficult to appreciate how sildenafil, simply by coincidence, would interfere with these distinctly different mechanisms to produce essentially the same net effect. Rather, it seemed more likely that sildenafil would interfere with a singular action that these structurally-unrelated antidiabetic agents might have in common. One action that metformin and thiazolidinediones are known to have in common is stimulation of glucose uptake (59–66), which increases availability of glucose to intracellular storage and utilization. And this occurs in arterial vascular smooth muscle cells as well (59–61, 66) where such increased glucose uptake can potentially support active (ATP-driven) relaxant as well as contraction-enhancing mechanisms.
In vascular smooth muscle, carbohydrate metabolism and the role it plays in relaxation as well as contraction is highly compartmentalized (31, 32, 37–41, 67–69). There are at least two functionally independent Embden-Meyerhof (glycolytic) compartments (or pathways) in vascular smooth muscle (32, 39, 68, 69). One is localized deep in the cytosol (linked to contractile filaments) where it preferentially utilizes glucose-6-phosphate from breakdown of stored glycogen to provide acetyl-CoA for mitochondrial production of ATP to fuel contraction (31, 39, 41, 67–69). The others (also called lactate-producing glycolysis compartments) are associated largely with the cell plasma membrane (PM) and membranes of the sarcoplasmic reticulum (SR) (37–45, 70). These membrane-associated glycolytic pathways preferentially utilize glucose-6-phosphate directly from extracellular glucose to fuel at least the following four ATP-dependent ion transporters: PM-Ca-ATPase, Na/K-ATPase, ATP-sensitive K (K_{ATP}) channels and SR-Ca-ATPase (37–45, 70). Supported by intracellular ATP, the first two of these four transporters can potentially relax (inhibit) contractions exerted by vasoconstrictors such as norepinephrine (by maintaining specific cell membrane cation gradients and contributing to cell membrane polarization, 41, 71–75) while the latter two can potentially enhance (facilitate) norepinephrine contractions (37, 41–43, 45, 76–78). Increased intracellular ATP from glycolysis of extracellular glucose closes K_{ATP} channels (42–44). In rat tail artery, closure of K_{ATP} channels participates in norepinephrine-induced smooth muscle membrane depolarization (76) which in turn can potentially enhance (facilitate) contraction. SR-Ca-ATPase utilizes ATP from glycolysis of extracellular glucose to maintain optimum filling of norepinephrine-releasable intracellular SR Ca stores (37, 41, 45). There is evidence that this filling involves opening of specific store-operated Ca channels in the cell plasma membrane in close proximity to SR-Ca-ATPase in the SR membrane (79). If filling of the SR with Ca in this manner is compromised by omission of extracellular glucose, norepinephrine contraction is reduced (37, 41, 45). Thus, while it is generally accepted that uptake of extracellular glucose supports norepinephrine contraction by maintaining optimal intracellular glycogen levels (80), it is also known to do so by maintaining optimal SR Ca levels (37, 41, 45).

Therefore, given the common ability of the antidiabetic drugs to stimulate glucose uptake in arterial vascular smooth muscle (and thereby potentially affect norepinephrine contractility), we decided to conduct two additional experiments. Results from these experiments are shown in Figs. 4 and 5. Essentially, we found that 1) omission of extracellular glucose and 2) specific inhibition of the vascular smooth muscle lactate-producing glycolytic pathways (described above) completely abolished sildenafil’s anti-vasorelaxant interaction with the antidiabetic drugs. In addition, these same two interventions (especially the glucose omission) notably increased the magnitude of the antidiabetic drug-induced vasorelaxations; indeed markedly so for the thiazolidinediones. Accordingly, we strongly suspect that in addition to activating the abovementioned ion channel-based smooth muscle relaxant (inhibitory) mechanisms which inherently do not require extracellular glucose (43, 51), these antidiabetic agents also activate contraction-facilitating mechanisms that 1) do require glucose and 2) mask the full potential of their relaxant (inhibitory) mechanisms. Furthermore, we conclude that sildenafil’s anti-vasorelaxant interaction with these antidiabetic agents, as observed in the presence of extracellular glucose and fully intact glycolysis (Figs. 1–3), most likely involves enhancement of whatever glucose/glycolysis-dependent contraction-facilitating mechanisms they possess.

In other words, while the abovementioned effects of metformin and thiazolidinediones on voltage-operated channels (17, 20, 51–53) are the most likely mechanisms for the relaxant (inhibitory) effects we observed in the absence of extracellular glucose (Fig. 4) and in the presence of a specific inhibitor of the lactate-producing glycolysis pathways (Fig. 5), these are not the mechanisms affected by sildenafil. Rather, sildenafil must be interacting with glucose/glycolysis-dependent mechanisms. Accordingly, it is then reasonable to hypothesize that sildenafil may be interacting with the antidiabetic drugs at the level of the four abovementioned glucose/glycolysis-dependent contraction-facilitating mechanisms they possess.
glycolysis-dependent ion transporters, i.e. Na/K-ATPase, PM-Ca-ATPase, K\textsubscript{ATP} channels and SR-Ca-ATPase. We hypothesize that altered activity of one or more of these four ATP-dependent ion transporters is involved in mediating the novel attenuating (anti-vasorelaxant) interaction of sildenafil with metformin, pioglitazone and rosiglitazone that we observed. We intend to test this hypothesis in the future beginning by measuring effects of specific inhibitors of those four transporters on the ability of sildenafil to attenuate antidiabetic drug-induced vasorelaxations. Such experiments are beyond the scope and funding of the present study.

**Clinical relevance**

Hypertension is a highly prevalent difficult-to-control condition in type 2 diabetic patients (81–87) and little attention has been given to whether PDE5 inhibitors interact with any of the known therapeutic actions of the abovementioned antidiabetic agents, particularly their well-documented blood pressure lowering action (49, 56, 81–106). Our data clearly raise a question whether PDE5 inhibitors might compromise that action by interfering with the one mechanism most likely responsible for it (i.e. their arterial vasorelaxant effects). We are unaware of any clinical studies designed specifically to address this concern. But we are aware of one study in which adult men were treated simultaneously with pioglitazone (at a dose known to lower arterial pressure) and sildenafil to determine how their erectile dysfunction was affected (107). After nine weeks, pioglitazone (30 mg daily versus placebo) improved their erectile responsiveness to sildenafil but, interestingly, failed to lower either their systolic or diastolic arterial pressures (107). And according to some of the blood pressure lowering reports cited above (82, 85, 88, 103), in which the same dose of pioglitazone (in the absence of PDE5 inhibition) did indeed lower arterial pressures, nine weeks is more than enough time for it to do so. On the other hand, our data clearly do not provide any evidence that sildenafil will interact with either pioglitazone, rosiglitazone or metformin to cause life-threatening episodes of severe hypotension when used to treat diabetic men. And to our knowledge, there are no reports of such episodes in that population.

---

**Acknowledgements**

This study was supported by funds from the Viagra Grants Program and from Midwestern University. The authors wish to acknowledge the assistance of Victoria Sears in the preparation of the manuscript and Catherine Lencioni for assisting in the search for an appropriate journal.

---

**Conflict of Interest**

The authors declare they have no conflict of interest.

---

**References**

1. Ishizuka N, Saito K, Akima M, Matsubara S, Saito M. Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. Jpn J Pharmacol. 2000; 84(3): 316–24.
2. Kruuse C, Khurana TS, Rybalkin SD, Birk S, Engel U, Edvinsson L, Olesen J. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. Eur J Pharmacol. 2005; 521(1–3): 105–14.
3. Lucas KA, Pitarri GM, Kazeronian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000; 52(3): 375–414.
4. Medina P, Segarra G, Martínez-León JB, Vila JM, Aldasoro M, Otero E, Lluch S. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann Thorac Surg. 2000; 70(4): 1327–31.

5. Salom JB, Burguete MC, Perez-Asensio FJ, Castello-Ruiz M, Torregrosa G, Alborch E. Relaxant effect of sildenafil in the rabbit basilar artery. Vascul Pharmacol. 2006; 44(1): 10–6.

6. Schlossmann J, Hofmann F. cGMP-dependent protein kinases in drug discovery. Drug Discov Today. 2005; 10(9): 627–34.

7. Sharabi FM, Daabees TT, El-Metwally MA, Senbel AM. Effect of sildenafil on the isolated rat aortic rings. Fundam Clin Pharmacol. 2005; 19(4): 449–56.

8. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006; 316(2): 654–61.

9. Vesely DL. Signal transduction: activation of the guanylate cyclase-cyclic guanosine-3’-5’ monophosphate system by hormones and free radicals. Am J Med Sci. 1997; 314(5): 311–23.

10. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999; 83(5A): 3C–12C.

11. Carson CC, III. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005; 96(12B): 37M–41M.

12. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000; 36(1): 25–31.

13. Cohen JS. Sildenafil and nonnitrate antihypertensive medications. JAMA. 2000; 283(2): 201–2.

14. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978; 24(6): 683–93.

15. Souri E, Jalalizadeh H, Saremi S. Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study. J Chromatogr Sci. 2008; 46(9): 809–12.

16. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002; 62(12): 1805–37.

17. Chen XL, Panek K, Rembold CM. Metformin relaxes rat tail artery by repolarization and resultant decreases in Ca2+ influx and intracellular [Ca2+]. J Hypertens. 1997; 15(3): 269–74.

18. Lee JM, Peuler JD. Acute vasorelaxant effects of metformin and attenuation by stimulation of sympathetic agonist release. Life Sci. 1999; 64(4): L57–L63.

19. Peuler JD, Miller JA, Bourghi M, Zammam HY, Soltis EE, Sowers JR. Disparate effects of antidiabetic drugs on arterial contraction. Metabolism. 1997; 46(10): 1199–205.

20. Peuler JD, Lee JM, Smith JM. 4-Aminopyridine antagonizes the acute relaxant action of metformin on adrenergic contraction in the ventral tail artery of the rat. Life Sci. 1999; 65(23): PL287–93.

21. Peuler JD, Warfield RK, Phelps LE. Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazone. Metabolism. 2004; 53(2):147–52.

22. Peuler JD, Wahler GM, Smith JM. Thapsigargin blocks relaxation of arterial smooth muscle by metformin. Am J Hypertens. 2001; 14: 220A.

23. Peuler JD. Differential effects of a thiazolidinedione and a biguanide on intracellular calcium dependent contractions in vascular smooth muscle. The FASEB Journal. 2002; 16: A938.

24. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002; 25(2): 284–91.
25. Spollett GR. Assessment and management of erectile dysfunction in men with diabetes. Diabetes Educ. 1999; 25(1): 65–73.
26. Medgett IC. alpha 2-Adrenoceptors mediate sympathetic vasoconstriction in distal segments of rat tail artery. Eur J Pharmacol. 1985; 108(3): 281–7.
27. Rajanayagam MA, Medgett IC. Greater activation of smooth muscle alpha-2 adrenoceptors by epinephrine in distal than in proximal segments of rat tail artery. J Pharmacol Exp Ther. 1987; 240(3): 989–97.
28. Souza FM, Padilha AS, Stefanon I, Vassallo DV. Differences in functional and structural properties of segments of the rat tail artery. Braz J Med Biol Res. 2008; 41(5): 416–23.
29. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002; 53 Suppl 1: S5–S12S.
30. Arnqvist HJ. Effects of increasing glucose concentrations on the glucose metabolism in arterial tissue and intestinal smooth muscle. Acta Physiol Scand. 1973; 88(4): 481–90.
31. Lynch RM, Kuettner CP, Paul RJ. Glycogen metabolism during tension generation and maintenance in vascular smooth muscle. Am J Physiol. 1989; 257(4 Pt 1): C736–C742.
32. Barron JT, Kopp SJ, Tow JP, Messer JV. Effects of altering carbohydrate metabolism on energy status and contractile function of vascular smooth muscle. Biochim Biophys Acta. 1989; 976(1): 42–52.
33. Barron JT, Kopp SJ, Tow JP, Parrillo JE. Differential effects of fatty acids on glycolysis and glycogen metabolism in vascular smooth muscle. Biochim Biophys Acta. 1991; 1093(2–3): 125–34.
34. El Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol. 2004; 46(4): 503–9.
35. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004; 47(11): 1914–23.
36. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999; 281(5): 421–6.
37. Adams GR, Dillon PF. Glucose dependence of sequential norepinephrine contractions of vascular smooth muscle. Blood Vessels. 1989; 26(2): 77–83.
38. Campbell JD, Paul RJ. The nature of fuel provision for the Na+,K(+)-ATPase in porcine vascular smooth muscle. J Physiol. 1992; 447: 67–82.
39. Dominguez LJ, Peuler JD, Sowers JR. Contemporary Endocrinology: Endocrinology of the Vasculature. Humana Press Inc.; 1996. Endocrine regulation of vascular smooth muscle intermediary metabolism.; p.325–39.
40. Paul RJ. Smooth muscle energetics. Annu Rev Physiol. 1989; 51: 331–49.
41. Zhang C, Paul RJ. Excitation-contraction coupling and relaxation in porcine carotid arteries are specifically dependent on glucose. Am J Physiol. 1994; 267(5 Pt 2): H1996–H2004.
42. Lorenz JN, Schnerrmann J, Brosius FC, Briggs JP, Furspan PB. Intracellular ATP can regulate afferent arteriolar tone via ATP-sensitive K+ channels in the rabbit. J Clin Invest. 1992; 90(3): 733–40.
43. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995; 268(4 Pt 1): C799–C822.
44. Weiss JN, Lamp ST. Glycolysis preferentially inhibits ATP-sensitive K+ channels in isolated guinea pig cardiac myocytes. Science. 1987; 238(4823): 67–9.
45. Martinez-Zaguilan R, Wesson DE. Regulation of endoplasmic reticulum-Ca-ATPase by glycolysis in eukaryotic cells. Miner Electrolyte Metab. 1996; 22(5–6): 318–35.
46. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 2005; 7(6): 675–91.
47. Seufert J, Lubben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther. 2004; 26(6): 805–18.

48. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006; 49(3): 434–41.

49. Kirpichnikov D, McFarlane SL, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137(1): 25–33.

50. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003; 63(13): 1373–405.

51. Nakamura Y, Ohyu Y, Onaka U, Fujii K, Abe I, Fujishima M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998; 123(4): 675–82.

52. Eto K, Ohyu Y, Nakamura Y, Abe I, Fujishima M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol. 2001; 423(1): 1–7.

53. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994; 24(2): 170–5.

54. Bhalia RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens. 1996; 9(6): 570–6.

55. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest. 1995; 96(1): 354–60.

56. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5): 529–36.

57. Sung BH, Izzo JL Jr., Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999; 34(1): 83–8.

58. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension. 1994; 24(1): 106–10.

59. Ofenstein JP, Dominguez LJ, Sowers JR, Sarndaik AP. Effects of insulin and metformin on glucose metabolism in rat vascular smooth muscle. Metabolism. 1999; 48(11): 1357–60.

60. Domingueze LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology. 1996; 137(1): 113–21.

61. Sasson S, Gorovits N, Joost HG, King GL, Cerasi E, Kaiser N. Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells. Br J Pharmacol. 1996; 117(6): 1318–24.

62. Klip A, Guma A, Ramlal T, Bilan PJ, Lam L, Leiter LA. Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinology. 1992; 130(5): 2535–44.

63. Standeaert ML, Kanoh Y, Sajan MP, Bandypadhyay G, Farese RV. Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology. 2002; 143(5): 1705–16.

64. el Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism. 1994; 43(8): 953–8.

65. Hofmann C, Lorenz K, Colca JR. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology. 1991; 129(4): 1915–25.

66. Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, Yamashita S, Matsuzawa Y. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis. 1998; 136(1): 163–8.

67. Lynch RM, Paul RJ. Compartmentation of glycolytic and glycogenolytic metabolism in vascular smooth...
muscle. Science. 1983; 222(4630): 1344–6.

68. Lynch RM, Paul RJ. Compartmentation of carbohydrate metabolism in vascular smooth muscle: evidence for at least two functionally independent pools of glucose 6-phosphate. Biochim Biophys Acta. 1986; 887(3): 315–8.

69. Lynch RM, Paul RJ. Compartmentation of carbohydrate metabolism in vascular smooth muscle. Am J Physiol. 1987; 252(3 Pt 1): C328–C334.

70. Paul RJ, Hardin CD, Raeymaekers L, Wuytack F, Casteels R. Preferential support of Ca\(^{2+}\) uptake in smooth muscle plasma membrane vesicles by an endogenous glycolytic cascade. FASEB J. 1989; 3(11): 2298–301.

71. Anderson DK. Cell potential and the sodium-potassium pump in vascular smooth muscle. Fed Proc. 1976; 35(6): 1294–7.

72. Lynch CJ, Steer ML, Smart JL, Deth RC. Differences in the role of Na\(^+/\)K\(^{-}\)-ATPase during alpha 1-adrenergic events in rat and rabbit aorta. Pharmacology. 1986; 33(4): 221–34.

73. Lynch RM, Paul RJ. Glucose uptake in porcine carotid artery: relation to alterations in active Na\(^+\)-K\(^+\) transport. Am J Physiol. 1984; 247(5 Pt 1): C433–C440.

74. O’Donnell ME, Owen NE. Regulation of ion pumps and carriers in vascular smooth muscle. Physiol Rev. 1994; 74(3): 683–721.

75. Oktay S, Ilhan M. Effect of ouabain on norepinephrine-induced contractions of isolated rabbit aorta. Pharmacology. 1988; 37(2): 69–74.

76. Tan JH, Al AA, Brock JA. Inhibition of KATP channels in the rat tail artery by neurally released noradrenaline acting on postjunctional alpha2-adrenoceptors. J Physiol. 2007; 581(Pt 2): 757–65.

77. Luo D, Nakazawa M, Yoshida Y, Cai J, Imai S. Effects of three different Ca\(^{2+}\) pump ATPase inhibitors on evoked contractions in rabbit aorta and activities of Ca\(^{2+}\) pump ATPases in porcine aorta. Gen Pharmacol. 2000; 34(3): 211–20.

78. Low AM, Kotecha N, Neild TO, Kwan CY, Daniel EE. Relative contributions of extracellular Ca\(^{2+}\) and Ca\(^{2+}\) stores to smooth muscle contraction in arteries and arterioles of rat, guinea-pig, dog and rabbit. Clin Exp Pharmacol Physiol. 1996; 23(4): 310–6.

79. Blaustein MP, Golovina VA, Song H, Choate J, Lencesova L, Robinson SW, Wier WG. Organization of Ca\(^{2+}\) stores in vascular smooth muscle: functional implications. Novartis Found Symp. 2002; 246: 125–37.

80. Barron JT, Barany M, Gu L, Parrillo JE. Metabolic fate of glucose in vascular smooth muscle during contraction induced by norepinephrine. J Mol Cell Cardiol. 1998; 30(3): 709–19.

81. de Rivas B, Luque M, Martell N, Fernandez C, Fernandez-Cruz A. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. J Clin Hypertens (Greenwich). 2007; 9(7): 530–7.

82. Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep. 2007; 9(4): 332–7.

83. Kelly AS, Bank AJ. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications. 2007; 21(5): 326–34.

84. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des. 2009; 15(27): 3179–92.

85. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press. 2006; 15(3): 135–50.

86. Sarafidis PA. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam Clin Pharmacol. 2008; 22(3): 247–64.

87. Takahashi A, Kushiro T. [Pioglitazone effects on blood pressure in patients with metabolic syndrome]. Nihon Rinsho. 2008; 66(8): 1591–5.
88. Abe M, Okada K, Kikuchi F, Matsumoto K. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2 diabetic patients undergoing hemodialysis. Clin Nephrol. 2008; 70(3): 220–8.

89. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006; 24(10): 2047–55.

90. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, Wilding JP. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004; 21(5): 415–22.

91. Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther. 2005; 27(9): 1383–91.

92. Derosa G, Fogari E, Cicero AF, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007; 30(5): 387–94.

93. Gerber P, Lubben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003; 19(6): 532–9.

94. Giugliano D, De RN, Di MG, Marfella R, Acampora R, Buoninconti R, D’Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993; 16(10): 1387–90.

95. Grossman E. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. J Hum Hypertens. 2003; 17(1): 5–6.

96. Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care. 2003; 26(11): 3194–5.

97. Jin HM, Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res. 2007; 30(4): 203–11.

98. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambarini A, Jones NP, Gomis R, Home PD. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol. 2008; 7: 10.

99. Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther. 1992; 17(2): 75–9.

100. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991; 229(2): 181–7.

101. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril. 2009; 91(6): 2527–36.

102. Mador - Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000; 31(6): 571–5.

103. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004; 29(1): 11–7.

104. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and
metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005; 70(1): 20–5.

105. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003; 26(1): 172–8.

106. Schondorf T, Forst T, Hohberg C, Pahler S, Link C, Roth W, Pfutzner A, Lubben G, Link C, Pfutzner A. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab. 2007; 9(1): 132–3.

107. Gholamine B, Shafiei M, Motevallian M, Mahmoudian M. Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. J Pharm Pharm Sci. 2008; 11(1): 22–31.